Judith M. Matthews is CFO at Iterum Therapeutics plc (ITRM). They have made 5 open-market trades across 1 company since 2018, most recently 2023-03-11.
CIK 0001734033
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $52K since 2018, against 4 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ITRM | 11,018 | $347 |
Shares reported on the most recent Form 4, priced at the 2023-03-14 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ITRM | SELL | 2022-03-14 | 2022-03-15 | $0.38 | $18K | +31.5% | -9.9% | -37.7% |
| ITRM | SELL | 2022-03-14 | 2022-03-15 | $0.31 | $20K | +31.5% | -9.9% | -37.7% |
| ITRM | SELL | 2021-01-26 | 2021-01-27 | $1.73 | $117K | +6.2% | +13.1% | -17.2% |
| ITRM | SELL | 2020-09-30 | 2020-10-02 | $1.64 | $184K | -5.3% | -54.1% | -1.3% |
| ITRM | BUY | 2018-05-30 | 2018-05-30 | $13.00 | $52K | -3.9% | -14.6% | -18.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.